Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temporal kinetics of antibody and cellular responses and impact of revaccination after COVID-19 monoclonal antibody treatment
2024-514071-17-00Phase 4Authorised
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran, tixagevimab + cilgavimab, sotrovimab and NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Planned start Jul 2024; status: authorised.
02
Drugs
tozinameranelasomerantixagevimab + cilgavimabsotrovimabNVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-514071-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514071-17-00.